Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care
2018; Elsevier BV; Volume: 33; Linguagem: Inglês
10.1016/j.blre.2018.07.003
ISSN1532-1681
AutoresMoussab Damlaj, Riad El Fakih, Shahrukh K. Hashmi,
Tópico(s)Cancer Treatment and Pharmacology
ResumoRecent advancements in cancer care, coupled with early detection and an aging population have resulted in significant growth of cancer survivors. Long term follow up of such survivors is essential given the heightened risk for development of late effects such as secondary neoplasms, cardiovascular disease or psychosocial dysfunction among others. As more patients with hematologic malignancies are cured or managed over protracted periods of time, awareness of such issues is paramount for the practicing clinicians for optimal patient management. In this review, we describe the genesis of the field of cancer survivorship, and then it's gentle metamorphosis into multiple sub-fields currently by presenting literature relevant to late effects commonly seen in Hodgkin lymphoma, non-Hodgkin lymphoma, chronic leukemia and multiple myeloma. We will discuss the strengths and pitfalls of the existing models of survivorship care in hematologic malignancies and conclude with expert perspective on how to move the field forward.
Referência(s)